SEC For	rm 4 FORM	4	UNITED) STA	TES S	ECUR	ITIE	S ANI	ΣE	XCHA	NGE	ECC	оммі	SSION				
	-			Washington, D.C. 20549									OMB APPROVAL			VAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STAT		d pursuan	it to Section	n 16(a)) of the Se	ecuritie	Ses Exchanges Exchanges	ge Act	t of 19:	-	HIP	Estim	Number: ated aver per resp	rage burder	3235-0287 n 0.5
1. Name and Address of Reporting Person [*] Rawcliffe Adrian						2. Issuer Name and Ticker or Trading Symbol Wave Life Sciences Ltd. [WVE]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 08/12/2024								Officer (give title Other (specify below) below)				specify
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE.					4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable ine) Form filed by One Reporting Person				
(Street) CAMBRIDGE MA 02138					Rule 10b5-1(c) Transaction Indication									Form filed by More than One Reporting Person				
(City)	(S	·	(Zip) Die I - Nor	n-Deriv	Che sati	eck this box isfy the affin	to indic mative	cate that a t defense co	transa nditior	action was m ns of Rule 10	iade pu 0b5-1(d	ursuant c). See	Instructio			plan that	t is intended	1 to
1. Title of Security (Instr. 3) 2. Transa Date				action Day/Year)	Execution if any	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					4 and Securities Beneficiall Owned Fol		Form:	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount		(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Ordinary Shares 08/12					/2024		Α		16,115 ⁽¹⁾ A		\$ <mark>0</mark>	16	,115		D			
		1	Table II -	Derivat (e.g., p	tive Sec uts, cal	curities IIs, warr	Acqu ants	uired, D , option	ispo is, c	osed of, convertit	or B ble s	Benef ecur	ficially ities)	Owned			· · ·	
			ransaction of E ode (Instr. Derivative (I		Expiration	5. Date Exercisable and Expiration Date Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e C s F illy E g (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Г					Т				Amount					

				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Number of Shares			
Shar Optiv (righ buy)	nt to	\$5.37	08/12/2024	Α		32,230		(2)	08/12/2029	Ordinary Shares	32,230	\$0.00	32,230	D

Explanation of Responses:

1. The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025.

2. The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2025 annual general meeting or August 12, 2025.

/s/ Adrian Rawcliffe	

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

08/14/2024

Date